Abstract | PURPOSE: METHODS: MONITOR-GCSF was a prospective, observational, multicenter, pan-European study of 1447 chemotherapy-treated patients receiving daily biosimilar (standard) filgrastim (Zarzio®/Zarxio®, filgrastim-sndz, Hexal AG, Sandoz Inc.). In this analysis, cycles were classified as same-day, per-guidelines, or late if G-CSF support was initiated < 24 h, 24-72 h, and > 72 h after chemotherapy. Outcomes included occurrence of CIN of any grade (CIN1/4), grade 3 or 4 (CIN3/4), grade 4 (CIN4), or FN: CIN/FN-related hospitalization or CIN/FN-related chemotherapy disturbance. RESULTS: A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF initiation: 795 cycles (13.4%) classified as same-day, 3320 (56.0%) as per-guidelines, and 1815 (30.6%) as late. Groups did not differ as to CIN1/4 and FN episodes, or CIN/FN-related hospitalizations or chemotherapy disturbances. Patients in the same-day and per-guidelines groups had statistically similar odds of not experiencing any outcomes of interest in any given cycle. Patients in the late group had worse odds of experiencing CIN1/4, CIN3/4, and CIN4 episodes in any given cycle. Proportions of patients reporting clinical events of interest were generally similar. CONCLUSIONS:
|
Authors | Heinz Ludwig, Pere Gascón, Carsten Bokemeyer, Matti Aapro, Mario Boccadoro, Kris Denhaerynck, Andriy Krendyukov, Karen MacDonald, Ivo Abraham |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 27
Issue 6
Pg. 2301-2312
(Jun 2019)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 30343410
(Publication Type: Journal Article)
|
Chemical References |
- Granulocyte Colony-Stimulating Factor
- Filgrastim
|
Topics |
- Aged
- Chemotherapy-Induced Febrile Neutropenia
(drug therapy, prevention & control)
- Female
- Filgrastim
(pharmacology, therapeutic use)
- Granulocyte Colony-Stimulating Factor
(pharmacology, therapeutic use)
- Humans
- Male
- Middle Aged
- Prospective Studies
|